Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

Executive Summary

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

You may also be interested in...



CMS Final Kidney Disease Treatment Model To Encourage More Home Dialysis

The US Medicare agency introduced a new end-stage renal disease treatment model on Friday to incentivize use of home dialysis.

COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio

Demand for Baxter's acute therapy products helped offset declines across its advanced surgery, pharmaceuticals and medication-delivery businesses in the second quarter.

FDA Clears Medtronic’s CRRT System For Pediatric Kidney Disease

The de novo clearance makes the Carpediem system the first commercially available system indicated for continuous renal replacement therapy in pediatric patients.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel